We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Illumina Comments on Roche’s Unsolicited Tender Offer Extension
News

Illumina Comments on Roche’s Unsolicited Tender Offer Extension

Illumina Comments on Roche’s Unsolicited Tender Offer Extension
News

Illumina Comments on Roche’s Unsolicited Tender Offer Extension

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Illumina Comments on Roche’s Unsolicited Tender Offer Extension"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Illumina, Inc. has issued the following statement regarding Roche’s decision to extend its unsolicited tender offer to acquire all outstanding shares of Illumina for $44.50 in cash per common share:

“The extension by Roche was expected. An extremely low number of shares have been tendered, consistent with our view - and that of our stockholders - that Roche’s offer does not reflect Illumina’s unique leadership position, business performance and future prospects.

“We remain focused on continuing to develop breakthrough products that expand existing markets and create new ones. The potential of our industry is enormous, with major new markets emerging in medical diagnostics, reproductive health and cancer management.”

Advertisement